D.E. Shaw & Co
KLDO

D.E. Shaw & Co’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

D.E. Shaw & Co’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-18,827
Closed -$45K – 6189
2021
Q4 		$45K Buy
+18,827
New +$76.7K ﹤0.01% 5217
2021
Q3 		– Sell
-10,483
Closed -$78K – 5512
2021
Q2 		$78K Buy
+10,483
New +$74.3K ﹤0.01% 4584

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's KLDO Position: Q1 2022 in Review

D.E. Shaw & Co sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q1 2022, closing a stake of 18,827 shares — an estimated $45K sold.

D.E. Shaw & Co first reported a position in KLDO in Q2 2021 and held it in 2 quarters. The position peaked at $78K in Q2 2021. 63 funds tracked by Wall St. Rank hold KLDO as of Q1 2022.

  • D.E. Shaw & Co reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 18,827 Kaleido Biosciences, Inc. Common Stock shares in Q1 2022, an estimated $45K.
  • D.E. Shaw & Co first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • D.E. Shaw & Co's Kaleido Biosciences, Inc. Common Stock position peaked at $78K in Q2 2021.
  • 63 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.